2023
Ischemic and Bleeding Outcomes in Patients Who Underwent Percutaneous Coronary Intervention With Chronic Kidney Disease or Dialysis (from a Japanese Nationwide Registry)
Tobe A, Sawano M, Kohsaka S, Ishii H, Tanaka A, Numasawa Y, Amano T, Nakamura M, Ikari Y, Murohara T. Ischemic and Bleeding Outcomes in Patients Who Underwent Percutaneous Coronary Intervention With Chronic Kidney Disease or Dialysis (from a Japanese Nationwide Registry). The American Journal Of Cardiology 2023, 195: 37-44. PMID: 37004333, DOI: 10.1016/j.amjcard.2023.02.027.Peer-Reviewed Original ResearchConceptsChronic kidney diseasePercutaneous coronary interventionPresence of CKDCKD stages 1Ischemic eventsAdjustment of covariatesHigh riskPCI registryCoronary interventionKidney diseaseNew-generation drug-eluting stent implantationDrug-eluting stent implantationUnderwent Percutaneous Coronary InterventionCKD stage 3Stage 1Bleeding eventsBleeding outcomesDialysis groupOral anticoagulantsCKD 3Renal functionStent implantationIncidence ratePatientsCare delivery
2020
Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia
Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. Journal Of Clinical Medicine 2020, 9: 1963. PMID: 32585929, PMCID: PMC7356748, DOI: 10.3390/jcm9061963.Peer-Reviewed Original ResearchAcute coronary syndromeDual antiplatelet therapyComposite ischemic eventsNovel P2Y12 inhibitorsAntithrombotic strategiesP2Y12 inhibitorsCoronary syndromeIschemic eventsWestern patientsTreatment platelet reactivityUse of clopidogrelPercutaneous coronary interventionCurrent clinical guidelinesStandard of careEast Asian patientsBorderline statistical differenceAntiplatelet therapyAntithrombotic therapyCoronary interventionClinical outcomesPlatelet reactivityAsian patientsHemorrhagic diathesisClinical guidelinesClinical studiesIschemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment
Shoji S, Sawano M, Sandhu A, Heidenreich P, Shiraishi Y, Ikemura N, Ueno K, Suzuki M, Numasawa Y, Fukuda K, Kohsaka S. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA Network Open 2020, 3: e202004. PMID: 32239221, PMCID: PMC7118520, DOI: 10.1001/jamanetworkopen.2020.2004.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAspirinBrain IschemiaCase-Control StudiesClopidogrelDeathDrug Therapy, CombinationFemaleHemorrhageHumansJapanMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideRegistriesRenal Insufficiency, ChronicRetrospective StudiesRisk AssessmentStrokeConceptsLow-dose prasugrelPercutaneous coronary interventionPrimary ischemic eventsAcute coronary syndromeBleeding eventsIschemic eventsCoronary syndromeST-segment elevation myocardial infarctionAcute Coronary Syndrome AssociatedPropensity score-matched analysisHigh-bleeding riskStandard-dose clopidogrelChronic kidney diseaseElevation myocardial infarctionPresent cohort studyShort-term outcomesEast Asian patientsReal-world outcomesPrasugrel treatmentClopidogrel administrationP2Y12 inhibitorsBaseline characteristicsClopidogrel treatmentCohort studyCoronary intervention